The 30-F1 monoclonal antibody specifically recognizes CD24 which is also known as Heat-Stable Antigen (HSA or HsAg). CD24 is a highly glycosylated sialoprotein that is glycosylphosphatidylinositol (GPI)-linked to the cell membrane. CD24 is encoded by Cd24a (CD24a antigen) and is variably expressed on thymocytes, lymphocytes, monocytes, granulocytes, and erythrocytes. Hematopoietic stem cells of the embryonic yolk sac and fetal liver express CD24. The expressed levels of CD24 vary during the developmental stages of cells within the T and B cell lineages. In the bone marrow, hematopoietic progenitors acquire CD24 expression upon commitment to the lymphocyte lineage. Immature B cells in the bone marrow and spleen of adult mice express high levels of CD24, whereas mature peripheral B cells express intermediate levels of CD24. The majority of thymocytes express high levels of CD24, whereas mature thymic and peripheral T cells do not express CD24. In contrast, γδ TCR-bearing thymocytes which emigrate to the spleen are CD24+. Dendritic cells of the thymus, spleen, and liver and epidermal Langerhans cells reportedly express CD24 whereas NK cells and plasma cells do not. CD24 can function as an adhesion molecule and serve as a ligand for CD62P (P-selectin). It can be involved in the costimulation of CD4+ T cells by B cells as well as function as a "co-inducer" of in vitro thymocyte maturation. 30-F1 and other CD24-specific monoclonal antibodies, such as, M1/69 and J11d, can show subtle differences in the staining patterns for different lymphocyte populations. For this reason, the consistent use of the same CD24-specific antibody is recommended during research studies.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
10. CF™ is a trademark of Biotium, Inc.
11. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from BD Horizon™ BV421 may be observed. Therefore, we recommend that individual compensation controls be performed for every BD Horizon™ BV605 conjugate.
12. BD Horizon Brilliant Violet 605 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
